Cure8 trial brief
Malnutrition is common in IBD and linked to worse quality of life and outcomes. Validating a standardized GLIM approach could help clinicians identify and treat malnutrition earlier and more consistently in people with Crohn's disease or ulcerative colitis.
Adult patients with IBD (Crohn's disease or ulcerative colitis), gastroenterologists, dietitians/nutritionists, and researchers studying nutrition and outcomes in IBD.
This is a registered prospective observational study (not yet recruiting) from Assiut University testing the Global Leadership Initiative on Malnutrition (GLIM) criteria for diagnosing malnutrition in adults with IBD using the Subjective Global Assessment (SGA) as the reference standard.
Enrolled patients will undergo nutritional risk screening (MUST or NRS-2002), anthropometry (including mid-arm and calf circumference), handgrip strength, dietary assessment, routine labs (CBC, CRP/ESR, LFTs, electrolytes) and fecal calprotectin; endoscopic scores (SES-CD or Mayo) will be recorded when available.
Planned primary outcomes are diagnostic performance metrics (sensitivity, specificity, PPV, NPV, Cohen's kappa) of GLIM versus SGA at baseline. Secondary aims include estimating prevalence and severity of GLIM-defined malnutrition, associations with clinical/functional/inflammatory measures, and identifying predictors of malnutrition in this IBD population.
The study will enroll adults (≥18) with confirmed Crohn's disease or ulcerative colitis managed at Al-Rajhi Liver Hospital; key exclusions include pregnancy, active malignancy, severe organ failure, marked edema/ascites, recent major surgery, or inability to consent.
This is a trial record for a prospective observational study that has not yet started recruiting. The registry provides planned methods and outcomes but does not include results. GLIM is a consensus framework; this study compares it to the Subjective Global Assessment (SGA) as the reference standard.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study explores breath VOCs as a possible noninvasive biomarker for IBD activity, which could offer easier, more acceptable monitoring than colonoscopy or stool tests.
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
